Clinical Trials
240 trialsShared Decision Making in Low Risk Prostate Cancer
Massachusetts General Hospital
PEM-PRO
IRCCS San Raffaele
TA-P-OLIM
University Hospital, Ghent
Immunotherapy Before and After Surgery
ImmunityBio, Inc.
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Robotic Telesurgery in Urology
Case Comprehensive Cancer Center
Superman
Canisius-Wilhelmina Hospital
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Patient Recall of Cancer Screening and Diagnosis
Case Comprehensive Cancer Center
PROTOMEN
University Hospital, Rouen
NeoPSMA
Novartis
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Oncology Institute of Southern Switzerland
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
University of Rochester
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
REPRESENTATION
Latin American Cooperative Oncology Group
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
CHEMOPROST
Institut Bergonié
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
DiaCarta, Inc.
TALON
Duke University
HRPCa-II
Assistance Publique - Hôpitaux de Paris
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
IRCCS San Raffaele
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
PROCeed-BR
AstraZeneca
Single-Port Versus Multi-Port Robotic Radical Prostatectomy
Case Comprehensive Cancer Center
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
Johnson & Johnson Private Limited
TOGETHER
Janssen Research & Development, LLC
Dynamic Whole Body PET/ MRI
British Columbia Cancer Agency
Prostate MRI and Pylarify PSMA PET/CT
Corewell Health East
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Sir Mortimer B. Davis - Jewish General Hospital
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
KOALA
Royal North Shore Hospital
LEPTO
RECORDATI GROUP
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Using Meditation for Oncology Anxiety
Geisinger Clinic
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
University of Alabama at Birmingham
Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors
Medical University of South Carolina
A Yoga Program for Patients Undergoing Prostate Cancer Surgery
VA Office of Research and Development
LUNAAR
Baptist Health South Florida
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Stanford University
TRACK
Western University, Canada
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center